Rigel Announces Participation at Two Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial officer of Rigel, will participate at two upcoming investor conferences. Details of the events are as follows:
Cowen and Company 33rd Annual Health Care Conference
Date: Wednesday, March 6 at 8:40 a.m. ET
Location: Boston, MA
Speaker: Ryan Maynard
25th Annual ROTH Conference
Date: Monday, March 18 at 4:00 p.m. PT
Location: Laguna Niguel, CA
Speaker: James M. Gower
Both events will be webcast live and can be accessed at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye.
Contact: Ryan Maynard
SOURCE Rigel Pharmaceuticals, Inc.
Released February 28, 2013